Peptides are everywhere right now.
They’re discussed on podcasts, promoted by wellness clinics and shared across social media as possible tools for metabolism, longevity, injury recovery and gut healing.
One peptide in particular—BPC-157—has attracted attention for its potential effects on inflammation and tissue repair. People often ask me whether it can “heal the gut.”
The honest answer is: possibly, but we don’t know enough yet.
BPC-157 may eventually prove useful in clinical care. For now, however, the excitement surrounding it has moved much faster than the human research.
What is BPC-157?
BPC-157 is a synthetic peptide made from a chain of 15 amino acids. Much of its popularity comes from laboratory and animal research examining its possible effects on injured tissue, inflammation and gastrointestinal healing. The FDA notes that BPC-157 is not currently an ingredient in an FDA-approved drug.
Animal research can help scientists identify promising treatments, but it cannot tell us with certainty whether those treatments will be safe or effective in people.
That requires well-designed human clinical trials.
Why is BPC-157 in the news?
In July 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157 and six other peptides for possible inclusion on the 503A Bulks List. This list identifies certain substances that may be used by qualifying pharmacies and physicians to prepare customized compounded medications.
The committee voted 8–6, with one abstention, to recommend adding BPC-157. It also recommended adding five of the six other peptides reviewed.
That was an important development—but it did not make BPC-157 an FDA-approved medication.
The FDA vote at a glance
The recommendation may mean… | It does not mean… |
|---|---|
BPC-157 could eventually become available through certain licensed compounding pharmacies. | BPC-157 is now FDA-approved. |
Access could move toward a more regulated, prescription-based pathway. | Its safety and effectiveness have been proven. |
More clinicians and researchers may pay attention to the peptide. | It works for every digestive or inflammatory condition. |
The FDA will consider the committee’s recommendation. | The FDA must accept the recommendation. |
The advisory vote is nonbinding. The FDA still has to decide whether BPC-157 should formally be added to the compounding list.
Compounded medications can meet important individual needs, but they are not FDA-approved. The FDA does not verify the safety, effectiveness or quality of each compounded medication before it is marketed.
What does the human research show?
For its review, the FDA evaluated BPC-157 specifically for ulcerative colitis. It did not find sufficient information to evaluate its proposed use for Crohn’s disease, celiac disease or tendonitis.
One small ulcerative-colitis study included 53 participants who received either BPC-157 or a placebo once daily for two weeks.
There were several significant limitations:
The BPC-157 was administered as a rectal enema, not as an oral capsule or injection.
The findings were presented only as a meeting abstract rather than a complete published study.
Important details about the participants, outcome measurements and follow-up were missing.
The FDA concluded that the available information was inadequate to establish effectiveness or safety.
The FDA identified only five small human studies involving BPC-157 across several different uses. These studies were brief, included relatively few participants and provided limited safety information.
That means we do not currently have enough evidence to conclude that BPC-157 is a proven treatment for:
IBS or SIBO
Bloating or reflux
Food reactions
Crohn’s disease or celiac disease
Intestinal permeability, often called “leaky gut”
General microbiome repair
The absence of strong evidence does not prove BPC-157 is ineffective. It means the larger claims being made about it have not yet been adequately tested in people.
A holistic approach is not one-size-fits-all
Holistic healthcare does not mean automatically choosing the most natural, newest or most popular intervention.
It means evaluating the whole person.
When someone comes to me with persistent digestive symptoms, I want to understand:
What symptoms are they experiencing?
What may be driving those symptoms?
What medications, diagnoses or previous treatments are part of the picture?
How are digestion, nutrition, stress, sleep and immune health affecting one another?
Which tools are appropriate for this individual—and which are not?
A peptide may eventually be one useful tool within a broader care plan. But it does not automatically identify why the gut is inflamed, irritated or struggling to heal.
Possible contributors may include microbiome imbalances, infections or overgrowth, reduced digestive function, changes in motility, medication use, chronic stress, immune activity and inadequate nutrition.
The best tool depends on the person—not the trend.
Promising is not the same as proven
BPC-157 deserves continued research. Its possible effects on tissue repair and gut health are interesting, and the recent advisory vote may eventually create a more supervised pathway for access.
But increased availability should not be confused with FDA approval or strong clinical evidence.
For now, the most accurate conclusion is:
BPC-157 may have therapeutic potential, but we do not yet have enough high-quality human research to call it a proven or broadly safe gut-healing treatment.
You can stay curious about new therapies without getting swept up in the marketing. When symptoms persist, the best place to start is with a clearer understanding of what is happening in your body—and which tools make sense for you.
About the Author
Emilie Davis, MScN, is a holistic and functional nutritionist specializing in gut health. She helps adults and children uncover possible contributors to persistent digestive, inflammatory and seemingly unrelated symptoms through individualized nutrition coaching and functional testing.
This article is for educational purposes and is not a substitute for individualized medical advice. Regulatory information is current as of July 2026.